-
June 19, 2013
Alnylam Pharmaceuticals R&D Day 2013We plan to host an R&D Day on July 11, 2013 in New York City. Alnylam scientists and management will review progress with our Alnylam 5×15 pipeline for the development of RNAi therapeutics.
View the invitation (0.9 MB PDF) Register for the webcast -
June 8, 2013
Upcoming Presentations at Scientific MeetingsWe plan to present updates from several of our “Alnylam 5×15″ programs at upcoming scientific meetings and events, including:
- International Conference on Complement Therapeutics being held June 18-23 in Kos, Greece (Presentation on Thursday, June 20)
- Biennial Meeting of the Peripheral Nerve Society being held June 29-July 3 in St. Malo, France (Presentation on Sunday, June 30)
- Congress of the International Society on Thrombosis and Haemostasis being held June 29-July 4 in Amsterdam (Presentation on Tuesday, July 2)
In addition, we plan to host an R&D Day on July 11, 2013 in New York City. Please email ir@alnylam.com for more information
-
May 17, 2013
New Pre-Clinical Data Presented from our ALN-AS1 Program for the Treatment of Acute Intermittent PorphyriaWe presented pre-clinical proof-of-concept data from our ALN-AS1 program for the treatment of acute intermittent porphyria (AIP) at the International Congress of Porphyrins and Porphyrias being held May 16 – 18, 2013. The research, presented by Alnylam scientists and collaborators at the Icahn School of Medicine at Mount Sinai in New York City, showed that administration of a GalNAc-conjugated siRNA targeting aminolevulinate synthase-1 (ALAS-1) blocked production of aminolevulinic acid (ALA) and porphobilinogen (PBG), the toxic precursors that cause disease symptoms and pathophysiology, in a mouse model of AIP.
View our presentation (1.6 MB PDF) Read our press release -
March 18, 2013
Phase I Clinical Study for ALN-TTRscWe initiated dosing in our Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR). The Phase I trial of ALN-TTRsc is being conducted in the U.K. as a randomized, double-blind, placebo-controlled, single- and multi-dose, dose-escalation study, enrolling up to 40 healthy volunteer subjects. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of subcutaneously administered ALN-TTRsc.
Read our press release Learn more about our ALN-TTR program
Recent Posts
-
June 13, 2013
Alnylam Corporate Overview, June 2013 Corporate Overview, June 2013 (2.o MB PPT) -
April 25, 2013
Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone MiceMajmudar et al., Circulation. 2013 Apr24 (Epub doi: 10.1161/CIRCULATIONAHA.112.000116) Continue reading…
-
December 8, 2012
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermediaSchmidt et al., Blood. 2013 Feb14 (Epub doi: 10.1182/blood-2012-09-453977 )
-
November 21, 2012
An immobilized and reusable Cu(i) catalyst for metal ion-free conjugation of ligands to fully deprotected oligonucleotides through click reaction.
